Securing sterile drug product capacity for early-phase development has never been more challenging. The revised EU GMP Annex 1 guidelines have raised expectations across contamination control, environmental monitoring, and aseptic process validation at precisely the moment global sterile capacity is under its greatest strain.
For early-stage biotech and emerging pharma, the impact is immediate. Timelines are extending, CMC packages are taking longer to complete, and the gap to Phase I is widening. This webinar cuts through the complexity. Upperton’s sterile development and operational experts will explain how the Annex 1 landscape is reshaping facility expectations, supply chain strategy, and early-phase development timelines.
You will also see how a structured, single-site approach can take a sterile programme from first formulation to a clinical submission-ready CMC package in as little as 16 weeks, subject to molecule readiness, scope, and prompt sponsor input.
This webinar will highlight practical strategies for navigating CDMO selection, Annex 1 with confidence, and how making informed early formulation decisions can achieve faster clinical submission readiness.
Securing sterile drug product capacity for early-phase development has never been more challenging. The revised EU GMP Annex 1 guidelines have raised expectations across contamination control, environmental monitoring, and aseptic process validation at precisely the moment global sterile capacity is under its greatest strain.
For early-stage biotech and emerging pharma, the impact is immediate. Timelines are extending, CMC packages are taking longer to complete, and the gap to Phase I is widening. This webinar cuts through the complexity. Upperton’s sterile development and operational experts will explain how the Annex 1 landscape is reshaping facility expectations, supply chain strategy, and early-phase development timelines.
You will also see how a structured, single-site approach can take a sterile programme from first formulation to a clinical submission-ready CMC package in as little as 16 weeks, subject to molecule readiness, scope, and prompt sponsor input.
This webinar will highlight practical strategies for navigating CDMO selection, Annex 1 with confidence, and how making informed early formulation decisions can achieve faster clinical submission readiness.
By ticking this box, you consent to receiving communications from Upperton related to this topic and other products or services within their portfolio